文献速递生殖医学

评估优化生育力低下女性妊娠结局的干预与辅助治疗:一项概述综述

Evaluating interventions and adjuncts to optimize pregnancy outcomes in subfertile women: an overview review.
PubMed 文献 · Hum Reprod Update · 2022-01-01

该概述综述汇总了截至2021年7月的75篇系统综述(含121251名参与者),评估生育力低下女性中各类干预对流产和活产的影响。中等以上质量证据支持宫内hCG(仅卵裂期移植)、男性抗氧化治疗、女性脱氢表雄酮及高透明质酸胚胎培养基可降低流产或改善活产;胚胎培养上清注射和FISH法PGT-A可能增加风险。

要点

  • 宫内hCG在卵裂期胚胎移植时有益,但囊胚移植时无此益处。
  • 男性抗氧化治疗、女性脱氢表雄酮及高透明质酸胚胎培养基有中等以上质量证据支持。
  • 胚胎培养上清注射和FISH法PGT-A可能增加流产或降低活产率。

核心结论

  • 该综述汇总了生育力低下女性中干预措施对流产和活产结局的系统综述证据,并指出有前景的干预方向及需高质量证据的领域。
  • 中等以上质量证据支持宫内hCG(卵裂期移植)、男性抗氧化治疗、女性脱氢表雄酮和高透明质酸胚胎培养基降低流产风险或改善活产机会。
  • 胚胎培养上清注射(冻融周期移植前)和FISH法PGT-A显示可能增加流产风险或降低活产率。

研究设计与样本

  • 检索Cochrane系统综述数据库和PubMed临床查询系统综述过滤器(从建库至2021年7月),纳入随机对照试验的系统综述。
  • 纳入生育力低下女性(已妊娠或尝试妊娠),干预对比安慰剂或无治疗,共纳入75篇系统综述、121251名参与者。
  • 采用GRADE方法评价证据质量,排除概述综述、仅报告自然受孕女性的综述、包含非随机研究设计的综述及未指定或报告流产或活产结局的综述。

主要发现

  • 共识别14类干预:黄体期支持、免疫治疗、抗凝剂、hCG、微量营养素、生活方式、内分泌、手术、非整倍体植入前遗传学检测(PGT-A)、实验室技术、子宫内膜损伤、ART方案、ART过程中其他辅助/技术及补充干预。
  • 中等以上质量证据支持降低流产风险或改善活产机会的干预包括:卵裂期胚胎移植时宫内hCG(但囊胚移植时无此益处)、男性抗氧化治疗、女性脱氢表雄酮及含高透明质酸的胚胎培养基。
  • 显示可能增加流产风险或降低活产率的干预包括:冻融周期胚胎移植前注射胚胎培养上清及使用荧光原位杂交(FISH)的PGT-A。

关键数值与推荐

  • 主要结局为流产,定义为妊娠<24周的妊娠丢失;活产数据在可获取时亦提取。
  • 中等以上质量证据支持:卵裂期胚胎移植时宫内hCG降低流产风险或改善活产机会,但囊胚移植时无此益处。
  • 中等以上质量证据支持:男性抗氧化治疗、女性脱氢表雄酮及含高透明质酸的胚胎培养基降低流产风险或改善活产机会。
  • 显示可能增加流产风险或降低活产率:冻融周期胚胎移植前注射胚胎培养上清及使用FISH的PGT-A。

临床怎么用

  • 该综述为临床医生和决策者提供简明汇总信息,帮助识别该领域的知识空白。
  • 作者指出需进一步研究以下有前景的干预:黄体期支持孕酮剂量、复发性种植失败女性外周血单核细胞、IVF女性糖皮质激素、不明原因生育力低下低分子肝素、卵裂期或囊胚移植时宫内hCG及胚胎培养低氧浓度。
  • 作者指出生殖外科领域需要高质量、设计良好的随机对照试验,并需进一步研究非药物生活方式干预的综合效果。

局限性

  • 需进一步研究黄体期支持孕酮剂量、复发性种植失败女性外周血单核细胞、IVF女性糖皮质激素、不明原因生育力低下低分子肝素、卵裂期或囊胚移植时宫内hCG及胚胎培养低氧浓度等有前景的干预。
  • 生殖外科领域需要高质量、设计良好的随机对照试验。
  • 需进一步研究非药物生活方式干预的综合效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a wealth of information regarding interventions for treating subfertility. The majority of studies exploring interventions for improving conception rates also report on pregnancy outcomes. However, there is no efficient way for clinicians, researchers, funding organizations, decision-making bodies or women themselves to easily access and review the evidence for the effect of adjuvant therapies on key pregnancy outcomes in subfertile women. OBJECTIVE AND RATIONALE: The aim was to summarize all published systematic reviews (SRs) of randomized controlled trials (RCTs) of interventions in the subfertile population, specifically reporting on the pregnancy outcomes of miscarriage and live birth. Furthermore, we aimed to highlight promising interventions and areas that need high-quality evidence. SEARCH METHODS: We searched the Cochrane Database of Systematic Reviews and PubMed clinical queries SR filter (inception until July 2021) with a list of key words to capture all SRs specifying or reporting any miscarriage outcome. Studies were included if they were SRs of RCTs. The population was subfertile women (pregnant or trying to conceive) and any intervention (versus placebo or no treatment) was included. We adopted Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for determining the quality of the evidence. Exclusion criteria were overview reviews, reviews that exclusively reported on women conceiving via natural conception, reviews including non-randomized study designs or reviews where miscarriage or live birth outcomes were not specified or reported. OUTCOMES: The primary outcome was miscarriage, defined as pregnancy loss <24 weeks of gestation. Data were also extracted for live birth where available. We included 75 published SRs containing 121 251 participants. There were 14 classes of intervention identified: luteal phase, immunotherapy, anticoagulants, hCG, micronutrients, lifestyle, endocrine, surgical, pre-implantation genetic testing for aneuploidies (PGT-As), laboratory techniques, endometrial injury, ART protocols, other adjuncts/techniques in the ART process and complementary interventions. The interventions with at least moderate-quality evidence of benefit in reducing risk of miscarriage or improving the chance of a live birth are: intrauterine hCG at time of cleavage stage embryo transfer, but not blastocyst transfer, antioxidant therapy in males, dehydroepiandrosterone in women and embryo medium containing high hyaluronic acid. Interventions showing potential increased risk of miscarriage or reduced live birth rate are: embryo culture supernatant injection before embryo transfer in frozen cycles and PGT-A with the use of fluorescence in situ hybridization. WIDER IMPLICATIONS: This review provides an overview of key pregnancy outcomes from published SRs of RCTs in subfertile women. It provides access to concisely summarized information and will help clinicians and policy makers identify knowledge gaps in the field, whilst covering a broad range of topics, to help improve pregnancy outcomes for subfertile couples. Further research is required into the following promising interventions: the dose of progesterone for luteal phase support, peripheral blood mononuclear cells for women with recurrent implantation failure, glucocorticoids in women undergoing IVF, low-molecular-weight heparin for unexplained subfertility, intrauterine hCG at the time of cleavage stage embryo or blastocyst transfer and low oxygen concentrations in embryo culture. In addition, there is a need for high-quality, well-designed RCTs in the field of reproductive surgery. Finally, further research is needed to demonstrate the integrated effects of non-pharmacological lifestyle interventions.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Holt-Kentwell A, Ghosh J, Devall A, et al. Evaluating interventions and adjuncts to optimize pregnancy outcomes in subfertile women: an overview review. Hum Reprod Update. 2022. PMID: 35137098. doi:10.1093/humupd/dmac001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。